Literature DB >> 1704186

Binding of tumor necrosis factor alpha to activated forms of human plasma alpha 2 macroglobulin.

G K Wollenberg1, J LaMarre, S Rosendal, S L Gonias, M A Hayes.   

Abstract

We tested the hypothesis that human plasma alpha 2 macroglobulin (alpha 2M) is a latent binding glycoprotein for human tumor necrosis factor alpha (TNF-alpha). Human recombinant 125I-TNF-alpha was incubated for 2 hours (37 degrees C) with purified native alpha 2M and with alpha 2M that was modified by reaction with methylamine or various proteinases. 125I-TNF-alpha/alpha 2M complexes were detected by nondenaturing polyacrylamide gel electrophoresis after autoradiography or by liquid chromatography on Superose-6. 125I-TNF-alpha bound strongly but noncovalently to alpha 2M-plasmin and alpha 2M-methylamine. There was minimal binding of 125I-TNF-alpha to native alpha 2M, alpha 2M-trypsin, or alpha 2M-thrombin. A 10(6) molar excess of porcine heparin did not reduce the binding of 125I-TNF-alpha to alpha 2M-methylamine or alpha 2M-plasmin. alpha 2M-plasmin or alpha 2M-methylamine added to human plasma or serum preferentially bound 125I-TNF-alpha in the presence of native alpha 2M. 125I-TNF-alpha also bound to 'fast' alpha-macroglobulins in methylamine-reacted human, rat, mouse, swine, equine, and bovine plasma. However, TNF-alpha, preincubated with either alpha 2M-plasmin or alpha 2M-methylamine, remained a potent necrogen for cultured L929 cells. Purified 125I-TNF-alpha/alpha 2M-plasmin complex injected intravenously in CD-1 mice rapidly cleared from the circulation, unless the alpha 2M-receptor pathway was blocked by coinjection of excess alpha 2M-trypsin. These findings demonstrate that alpha 2M is a latent plasmin-activated binding glycoprotein for TNF-alpha and that TNF-alpha/alpha 2M-plasmin complexes can be removed from the circulation by the alpha 2M-receptor pathway. This suggests that alpha 2M may be an important regulator of the activity and distribution of TNF-alpha in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704186      PMCID: PMC1886187     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  p-Nitrophenyl-p'-guanidinobenzoate HCl: a new active site titrant for trypsin.

Authors:  T Chase; E Shaw
Journal:  Biochem Biophys Res Commun       Date:  1967-11-30       Impact factor: 3.575

Review 2.  Tumor necrosis, cachexia, shock, and inflammation: a common mediator.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 3.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

4.  Interaction of nerve growth factor with murine alpha-macroglobulin.

Authors:  P H Koo; R W Stach
Journal:  J Neurosci Res       Date:  1989-03       Impact factor: 4.164

5.  Identification of alpha 2-macroglobulin as a cytokine binding plasma protein. Binding of interleukin-1 beta to "F" alpha 2-macroglobulin.

Authors:  W Borth; T A Luger
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

6.  Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor.

Authors:  P A Dennis; O Saksela; P Harpel; D B Rifkin
Journal:  J Biol Chem       Date:  1989-05-05       Impact factor: 5.157

7.  Identification of alpha 2-macroglobulin as a carrier protein for IL-6.

Authors:  T Matsuda; T Hirano; S Nagasawa; T Kishimoto
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

8.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

9.  Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex.

Authors:  T A McCaffrey; D J Falcone; C F Brayton; L A Agarwal; F G Welt; B B Weksler
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

10.  A human inhibitor of tumor necrosis factor alpha.

Authors:  P Seckinger; S Isaaz; J M Dayer
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  20 in total

Review 1.  The extracellular regulation of growth factor action.

Authors:  R Flaumenhaft; D B Rifkin
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

2.  Gene regulation networks related to neural differentiation of hESC.

Authors:  Jiang F Zhong; Yahui Song; Jing Du; Christine Gamache; Kathleen A Burke; Brett T Lund; Leslie P Weiner
Journal:  Gene Expr       Date:  2007

3.  Inhibition of intracellular proteolytic processing of soluble proproteins by an engineered alpha 2-macroglobulin containing a furin recognition sequence in the bait region.

Authors:  L Van Rompaey; T Ayoubi; W Van De Ven; P Marynen
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

4.  Malaria: a tumour necrosis factor inhibitor from parasitized erythrocytes.

Authors:  N A Sheikh; H N Caro; J Taverne; J H Playfair; T W Rademacher
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

Review 5.  Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense?

Authors:  M Schetz; P Ferdinande; G Van den Berghe; C Verwaest; P Lauwers
Journal:  Intensive Care Med       Date:  1995-02       Impact factor: 17.440

6.  Early supplemental α2-macroglobulin attenuates cartilage and bone damage by inhibiting inflammation in collagen II-induced arthritis model.

Authors:  Shengchun Li; Chuan Xiang; Xiaochun Wei; Xiaojuan Sun; Ruifang Li; Pengcui Li; Jian Sun; Dinglu Wei; Yong Chen; Yanxiang Zhang; Lei Wei
Journal:  Int J Rheum Dis       Date:  2019-01-04       Impact factor: 2.454

7.  Binding of platelet-derived growth factor-BB and transforming growth factor-beta 1 to alpha 2-macroglobulin in vitro and in vivo: comparison of receptor-recognized and non-recognized alpha 2-macroglobulin conformations.

Authors:  K P Crookston; D J Webb; J Lamarre; S L Gonias
Journal:  Biochem J       Date:  1993-07-15       Impact factor: 3.857

8.  Interaction of transforming growth factor-beta-1 with alpha-2-macroglobulin from normal and inflamed equine joints.

Authors:  N Coté; D R Trout; M A Hayes
Journal:  Can J Vet Res       Date:  1998-10       Impact factor: 1.310

9.  Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis.

Authors:  Shaowei Wang; Xiaochun Wei; Jingming Zhou; Jing Zhang; Kai Li; Qian Chen; Richard Terek; Braden C Fleming; Mary B Goldring; Michael G Ehrlich; Ge Zhang; Lei Wei
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

10.  Differences in the binding of transforming growth factor beta 1 to the acute-phase reactant and constitutively synthesized alpha-macroglobulins of rat.

Authors:  D J Webb; K P Crookston; N L Figler; J Lamarre; S L Gonias
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.